UNASSIGNED: The survival of @entity1 with @entity5 is decreased by locoregional recurrence after an initial multimodal treatment. In order to identify lesions in the oral cavity for a possible recurrence, clinical evaluation as well as MRI or CT scanning is advised. The evaluation of @entity75 is hampered by changes related to radio- and chemotherapy as well as reconstruction with tissue flaps. Several techniques for easier identification of tissue abnormalities in the oral cavity have been advocated as adjuncts in order to facilitate identification. Especially methods using altered tissue fluorescence have gained much interest during the last decade. The aim of our prospective study was to evaluate fluorescence properties of undiagnosed @entity75 with the @entity1652 in @entity1 with multimodal treated @entity5 prior to histological confirmation. In total, 41 @entity1 with a history of @entity957 ( @entity957 ) (19 females and 22 males) with undiagnosed @entity75 where included in the study. After clinical evaluation, examination and documentation using the VELscope   device were performed. Then, an incisional biopsy was performed. An autofluorescence loss indicating a malignant or @entity5932 could be detected in six @entity1 (14.6  %); however, only one @entity957 and one SIN revealed a complete autofluorescence loss. In four @entity1 , @entity957 was present in lesions with retained autofluorescence. Sensitivity and specificity for the VELscope   examination to identify malignant oral lesions by autofluorescence were 33.3 and 88.6  %, respectively. The positive and negative predictive values were 33.3 and 88.6  %, respectively. No statistical correlation between gender and lesion appearance versus autofluorescence loss could be detected. In contrast to @entity75 in @entity1 with no prior treatment, the autofluorescence evaluation with the VELscope reveals no additional information in our analysis. Accordingly, invasive biopsies as gold standard are still needed to get sufficient evidence regarding potential @entity5 in @entity1 after multimodal treatment for @entity5 .

Autofluorescence imaging in recurrent XXXX .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity1652 :: ('MESH:D009471', 'Disease') :: ['VELscope device'] @entity75 :: ('MESH:D001927', 'Disease') :: ['mucosa lesions'] @entity5 :: ('MESH:D009369', 'Disease') :: ['oral cancer', 'malignancy'] @entity957 :: ('MESH:D002294', 'Disease') :: ['oral squamous cell carcinomas', 'OSCC'] @entity5932 :: ('MESH:C565008', 'Disease') :: ['dysplastic mucosa condition']
@entity957 :: (MESH:D002294,Disease) :: ['oral squamous cell carcinoma']
